Special Issue

From Bench to Bedside: Expanding the Scope of Thioredoxin Reductase Inhibitors as Promising Therapeutics for Tumors, Inflammatory Disorders, and Infectious Diseases

Message from the Guest Editors

This Special Issue aims to select all in-depth studies that focus on expanding the understanding of current druggable structures, enhancing the synergic effects of combined medication, improving pharmacological function, and decreasing toxicological side-effects. These studies on druggable compounds or components include research on natural herb extracts, noble-metal complexes, or antioxidants for pharmaceutical application, and involving free radical research, redox biology, and tumor microenvironment regulation, are hereby very warmly welcome. The investigation of small molecule inhibitors and druggable components is not limited to the aforementioned natural resources, clinical drugs, or known structures, but could also be extended to creative chemicals, dyes, pigments, probes, nutrients, and biological trace elements. The purpose of this Special Issue is to call for all pharmaceutical and biotechnological opinions/studies on novel molecules/structures targeting cellular thioredoxin reductase, intended for clinical application in the effective therapy of human cancer, inflammations, and infectious diseases.

Guest Editors

Dr. Jianqiang Xu

School of Chemical Engineering, Ocean Technology and Life Science (CEOTLS), Dalian University of Technology, Panjin 124221, China

Prof. Dr. Jun Lu

College of Pharmaceutical Sciences, Southwest University, Chongqing 400715, China

Deadline for manuscript submissions

closed (25 October 2024)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/192429

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

